欢迎访问元和药业股份有限公司
科技研发
您的位置:首页 > Research > system  
Brief introduction about R & D center of Yuanhe pharmaceutical

Yuanhe pharmaceutical limited-liability company has its own independent R & D center. The building area is about 2000 Square meters, has Agilent 1100 High performance liquid chromatography,Agilent 8456  UV spectrophotometer,TLC scanner and freeze drying machine,continuous flow centrifuge, Fourier transform infrared spectrometer, atomic absorption spectrophotometer, microbial digestion instrument, infrared moisture meter, ambulatory blood pressure monitor and other advanced equipment , supporting facilities. The R & D center with Fudan University, Shanghai Institute of pharmaceutical industry, Second Military Medical University of medicine and the Inner Mongolia Medical University and other colleges and other major research institutions and institutions of higher learning have close relations of cooperation,with superior technical support and communication platform. The R & D center long-term employ many industry experts, PhD and professor of part-time in the company,to provide technical support during the process of implementation of the project. The R & D center has been awarded" Inner Mongolia yuanhe Mongolian Medicine Research Institute "," Hohhot City Business Development Center "," The Inner Mongolia Autonomous Region Mongolian Medicine Engineering Technology Research Center ", " The Inner Mongolia Autonomous Region enterprise research and Development Center ". At present, the center has created DDS technology platform, with the ability to develop controlled release formulations, transdermal absorption preparation, nano-preparation and so on.A number of research projects funded by Inner Mongolia science and technology department and Hohhot Bureau of science and technology,such as research of Mongolian medicine of generic technology,research of Mongolian medicine compound sea-buckthorn flavone tablets,quality standard and safety evaluationthe of Mongolian medicine Xinkang Capsule,Mongolian medicine compound Acorus four flavor preparation process and quality standard research,the establishment of Innovation DDS platform, research and development of fcinepolis-hydrochlorothiazide,Verapammil hydrochloride delayed release tablets and shengzhujing tablets.

R & D center developed Six new products for the company and obtained approval documents in recent years .Nine projects are in research and three projects has been declared,two products are in clinical research and four products has been listed in the market.

1.R & D center team 

    Wu Linxiang,the R&D center director,graduated from Inner Mongolia Medical University of medicine pharmacy,and engaged in researching drug about 30 years.   

    Wu Linxiang, President of Inner Mongolia Yuanhe Mongolian Pharmaceutical Research Institute,deputy general manager of Yuanhe pharmaceutical limited-liability company.There are 13 people in the research team,among them three people have senior professional titles.one people is doctorate,three people have master’s degree , seven people have bachelor’s degree.

2.product introduction

(1)Irbesartan and hydrochlorothiazide capsules (An Libo): antihypertensive compound, the exclusive production of dosage form, good absorption, high bioavailability, compared similar drug with significant effect. 

(2)Mao haori Chagan film-coated tablets (Shen zhujing): Mongolian medicine preparation by using modern technology research and development,it not only can invigorat the kidney and strengthen yang,nourish and strengthen body, and animal pharmacodynamic test demonstrated that it also can relieve fatigue,improve sleep and prevent and treat osteoporosis and so on. 

(3)sea-buckthorn Xuezhikang tablet: sea-buckthorn, seabuckthorn Xuezhikang is extracted from natural plant extract for effective ingredients,  high-tech products refined by science and technology.It is the most popular high-tech natural green health food after the deep sea fish oil and seal oil, lecithin,andit has significant advantage compared with other health food in market. 

(4)Verapammil hydrochloride delayed release tablets:

a.Development goal:Bioequivalence test of verapammil hydrochloride delayed release tablet results indicate that release delay four hours compared with the common reference preparation, other pharmacokinetic datas are same, namely that is biological equivalent compared with the common reference preparation, the biological equivalent results consistent with the project’s goals. The project is a new dosage form of medicine for treating hypertension (delayed release tablets). The project is a supplement to the existed forms for treating hypertension, in order adapt to features  of cardiovascular disease that rhythm of attack, to prevent hypertension, angina and other cardiovascular events (myocardial infarction, sudden cardiac death, stroke) .

Verapammil hydrochloride delayed release tablets for night released in the morning, namely take drug at bedtime ( In the evening ten clock ) ,release delay about 4~5h , the drug begin release in the morning 2~3 and two hours later reach Cmax, the maximum hypotensive effect at 5~6 clock.The antihypertensive effect continued at 8~9 clock in the morning at least.Make the peak levels of drug combined with sleep and activity to reach the purpose’s treatment, control of hypertension, angina and other cardiovascular events occurred in the morning .

b.The clinical characteristics

The purpose to study the preparation is to solve the problems in hypertensive patients at onset,to solve inconvenience of taking the drug in morning,can not effect immediately after taking the drug issue and to prevent cardiovascular accidents.For different patients, doctors can according to the need for treatment, when the patient wake up, can give the appropriate dose of Verapammil ordinary preparation again or use other antihypertensive drugs (including sustained-release preparation) or several antihypertensive drugs combination therapy, to achieve the goal of controlling blood pressure. 

c. Research progress. 

The II clinical study is ongoing.

(5)Gazha luoshu gel: Gazha luoshu gel is consist of Mongolian Shengcao wu, Shannai, Sanqi, Chuanxiong, its function is to regulate " Taking Heiyi, Badagan". To treat skin numbness, pain, paresthesia caused by diabetic peripheral neuropathy (DPN). At present, we obtained the patent (Patent No. 200510009240.9) and completed I clinical research and II clinical research is ongoing. 

(6)Mongolian medicine Xinkang Capsule: Xinkang Capsule is Mongolian medicine compound preparation, is composed of twelve herbs including Chenxiang,Muxiang, Hezi,Shijun zi,Zilu sha,Guangzao etc. It can calm,soothe the nerves, tonify heart, activating qi tonify qi,it is suitable for heart failure, atrial premature beat, ventricular premature,heart disease etc. The product obtained a patent (patent No.: CN200310120054.3).

0.2046s